Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24304063 | 0.77 | ADORA2A (0.35) | ADORA2BKDM4EALDH1A1GAAMAPT | |
| SCHEMBL29663145 | 0.67 | PIK3CD (0.35) | ADORA2B | |
| SCHEMBL29663177 | 0.66 | ADORA2B (0.33) | ADORA2B | |
| SCHEMBL29663450 | 0.66 | PIK3CD (0.32) | ADORA2B | |
| SCHEMBL23119748 | 0.64 | ADORA2B (0.44) | ADORA2BKDM4EHCRTR1ALDH1A1GAA | |
| SCHEMBL12193480 | 0.63 | MTOR (0.50) | ADORA2BKDM4EHCRTR1ALDH1A1GAA | |
| SCHEMBL15408051 | 0.62 | PDE3B (0.42) | — | |
| SCHEMBL14227442 | 0.61 | MTOR (0.39) | ADORA2BKDM4EALDH1A1MAPTPOLB | |
| SCHEMBL29663510 | 0.60 | JMJD6 (0.34) | ADORA2B | |
| SCHEMBL2243952 | 0.60 | DAO (0.58) | ALDH1A1POLBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-3999183-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | Ono Pharmaceutical Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM1B, KDM5D | ADORA2B 4430/4885KDM4E 16/4885HCRTR1 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.